Michael Carson
About Michael Carson
Michael Carson, 49, serves as Vice President of Finance and Corporate Secretary at Nuvectis Pharma (NVCT), a role he has held since March 2022. He brings 20+ years of corporate finance, accounting, and operations experience across biopharma and medical devices; he holds a BA in Business & Economics and a BS in Mechanical Engineering from Lafayette College and is a licensed CPA in Pennsylvania . The 2025 proxy notes he specializes in clinical-stage biotech finance; company-level TSR, revenue, and EBITDA performance metrics tied to his compensation are not disclosed for him (he is not a named executive officer) .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| XyloCor Therapeutics, Inc. | Vice President of Finance | Late 2019–2021 | Led accounting, treasury, and finance functions |
| Smiths Medical (Smiths Group division) | Global Controller (consultant) | 2019 | Led team covering accounting, treasury, and foreign currency exposure |
| Neuronetics (NASDAQ: STIM) | Director of FP&A | 2015–2019 | Second-in-command to CFO; strategic planning, financial execution, IR, controllership |
| Abbott Laboratories | Various finance/accounting roles | Prior to 2015 | Finance and accounting positions |
| Crowe LLP; Deloitte | Auditor | Early career | External audit experience |
External Roles
No public company directorships or external board roles disclosed for Michael Carson in the NVCT 2025 proxy .
Fixed Compensation
- Michael Carson is not listed as a Named Executive Officer in NVCT’s Summary Compensation Tables for 2024/2023; base salary, target bonus %, and cash payouts are not disclosed for him .
Performance Compensation
- Equity award terms for Carson are disclosed in ownership footnotes (restricted stock grant from 2021; see vesting below). No annual performance metric framework (e.g., revenue growth, EBITDA, TSR) or PSU design tied to his pay is disclosed in the proxy .
Equity Ownership & Alignment
| Metric | FY 2024 (Record date: Apr 15, 2024) | FY 2025 (Record date: Apr 14, 2025) |
|---|---|---|
| Common shares beneficially owned | 90,673 | 138,918 |
| Ownership % of common stock | * (denotes <1%) | * (denotes <1%) |
| Shares outstanding (context) | 18,370,758 | 23,606,443 |
- Hedging and pledging: NVCT’s Insider Trading Policy prohibits speculative trading, including hedging and pledging/short sales, applying to officers, directors, and employees .
- Section 16(a) compliance: The company reports Michael Carson filed one late Form 4 covering two transactions for FY 2024 .
Equity Grants and Vesting
| Grant Type | Grant Date | Shares | Vesting Schedule |
|---|---|---|---|
| Restricted Stock | Nov 1, 2021 | 27,300 | Two-thirds vested on the first two anniversaries; remaining one-third vest on Nov 1, 2024 |
Notes: NVCT’s policy prohibits timing option/stock award grant dates around MNPI; exercise/base price equals closing price on grant date; no options/SARs were granted to NEOs in blackout-adjacent windows during FY 2024 (Carson is not an NEO) .
Employment Terms
- Role and tenure: Vice President of Finance since March 2022; also Corporate Secretary empowered for proxy and shareholder communications .
- Contract specifics: No employment agreement, severance, change-of-control, non-compete/non-solicit, or clawback terms are disclosed specifically for Michael Carson in the 2025/2024 proxies (those narratives focus on CEO and other NEOs) .
- Insider Trading Policy: Prohibits hedging and pledging; codified in NVCT’s code and insider trading policy; policy filed with 2023 10-K exhibits .
Performance & Track Record
- Functional leadership: Carson’s biography emphasizes finance leadership in clinical-stage biotech and device organizations, including treasury, FX, controllership, FP&A, strategic planning, and investor relations responsibilities in prior roles .
- Corporate secretary responsibilities: He is designated to receive and process stockholder communications and proxy revocations; also an authorized proxy with the CEO for shareholder voting at the annual meeting .
Compensation Committee Analysis
- Committee composition (2024 activity): Kenneth Hoberman (Chair), Matthew Kaplan, and James Oliviero; five meetings and one unanimous written consent in FY 2024; members are independent under Nasdaq rules .
- Scope: Oversees CEO and CFO compensation and administers executive programs; discretion aligned with compensation philosophy; may engage consultants (none engaged in 2024; review possible in 2025) .
Investment Implications
- Alignment: Carson’s beneficial ownership increased from 90,673 (Apr 2024) to 138,918 (Apr 2025), indicating higher equity exposure and alignment, albeit still below 1% of outstanding shares .
- Selling pressure: A late Form 4 disclosure is a mild governance/compliance flag; absent detailed Form 4 cadence/size, pressure assessment is limited. Hedging/pledging prohibitions reduce misalignment risk .
- Retention risk and COC economics: With no disclosed employment agreement or severance/CIC protections for Carson, retention and payout certainty are unclear; unlike CEO/NEOs with detailed terms, this opacity limits modeling of exit/transition scenarios .
- Pay-for-performance signals: Lack of disclosed performance metric weights/targets for Carson constrains evaluation of incentive alignment to Company objectives; equity grants and ownership are the primary observable levers .